Cellectis SA
USUSDCellectis SA (LSE:0WA2) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om virksomheden
- Websted
- cellectis.com
- Investorrelationer
- cellectis.com/en/investors/governance/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- France, France
- Administrerende direktør
- Dr. Andre Choulika Ph.D.
- Ansatte
- 224
- Grundlagt
- 1999
- Børsnoteret siden
- 09.01.2018 (LSE:0WA2)
- Udestående aktier
- 72.72 mio.
- Free float
- 48.58 mio.
- Markedsværdi
- 148.06 mio. USD
- Insidere
- 0%
- Institutionelle investorer
- 15.36%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Juridisk form
- QVPB
- ISIN
- FR0010425595
- LEI
- 5493000KKX5VQ37Q2W83
Beskrivelse
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Udbytte
Ingen udbyttebetalinger fundet (tjekket 07.10.2026). Virksomheden udbetaler sandsynligvis ikke udbytte.
Nyheder denne uge
Endnu ingen nyheder fra virksomhedens websted.
Største ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| B Group, Inc. | 4.55% | 3.28 mio. | 2026-06-30 |
| Long Focus Capital Manag… | 3.8% | 2.74 mio. | 2026-06-30 |
| UBS AM, a distinct busin… | 3.67% | 2.64 mio. | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.33% | 235 696 | 2026-08-31 |
| Nomura Asset Management… | 0.31% | 226 875 | 2026-06-30 |
| Delaware Group Equity Fu… | 0.31% | 226 875 | 2026-06-30 |
| Blackrock Inc. | 0.31% | 225 444 | 2026-06-30 |
| Morgan Stanley | 0.12% | 85 455 | 2026-06-30 |
| LPL Financial LLC | 0.12% | 84 415 | 2026-06-30 |
| Susquehanna Internationa… | 0.07% | 50 453 | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.06% | 40 100 | 2026-06-30 |
| UBS Group AG | 0.05% | 33 926 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 1 949 | 2026-07-31 |
